193 related articles for article (PubMed ID: 11009620)
21. Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin.
Sáez-Calvo G; Sharma A; Balaguer FA; Barasoain I; Rodríguez-Salarichs J; Olieric N; Muñoz-Hernández H; Berbís MÁ; Wendeborn S; Peñalva MA; Matesanz R; Canales Á; Prota AE; Jímenez-Barbero J; Andreu JM; Lamberth C; Steinmetz MO; Díaz JF
Cell Chem Biol; 2017 Jun; 24(6):737-750.e6. PubMed ID: 28579361
[TBL] [Abstract][Full Text] [Related]
22. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Bai RL; Pettit GR; Hamel E
J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of interaction of vinca alkaloids with tubulin: catharanthine and vindoline.
Prakash V; Timasheff SN
Biochemistry; 1991 Jan; 30(3):873-80. PubMed ID: 1988072
[TBL] [Abstract][Full Text] [Related]
24. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
Lobert S; Frankfurter A; Correia JJ
Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
26. The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity.
Wieczorek M; Tcherkezian J; Bernier C; Prota AE; Chaaban S; Rolland Y; Godbout C; Hancock MA; Arezzo JC; Ocal O; Rocha C; Olieric N; Hall A; Ding H; Bramoullé A; Annis MG; Zogopoulos G; Harran PG; Wilkie TM; Brekken RA; Siegel PM; Steinmetz MO; Shore GC; Brouhard GJ; Roulston A
Sci Transl Med; 2016 Nov; 8(365):365ra159. PubMed ID: 27856798
[TBL] [Abstract][Full Text] [Related]
27. Energetics of vinca alkaloid interactions with tubulin.
Lobert S; Correia JJ
Methods Enzymol; 2000; 323():77-103. PubMed ID: 10944748
[No Abstract] [Full Text] [Related]
28. Theoretical insight into the structural mechanism for the binding of vinblastine with tubulin.
Chi S; Xie W; Zhang J; Xu S
J Biomol Struct Dyn; 2015; 33(10):2234-54. PubMed ID: 25588192
[TBL] [Abstract][Full Text] [Related]
29. Physiochemical aspects of tubulin-interacting antimitotic drugs.
Correia JJ; Lobert S
Curr Pharm Des; 2001 Sep; 7(13):1213-28. PubMed ID: 11472263
[TBL] [Abstract][Full Text] [Related]
30. Potential mechanisms of resistance to microtubule inhibitors.
Kavallaris M; Annereau JP; Barret JM
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
[TBL] [Abstract][Full Text] [Related]
31. Microtubule-disrupting effects of gallium chloride in vitro.
Perchellet EM; Ladesich JB; Collery P; Perchellet JP
Anticancer Drugs; 1999 Jun; 10(5):477-88. PubMed ID: 10477168
[TBL] [Abstract][Full Text] [Related]
32. BM6, a new semi-synthetic vinca alkaloid, exhibits its potent in vivo anti-tumor activities via its high binding affinity for tubulin and improved pharmacokinetic profiles.
Li W; Shao Y; Hu L; Zhang X; Chen Y; Tong L; Li C; Shen X; Ding J
Cancer Biol Ther; 2007 May; 6(5):787-94. PubMed ID: 17387272
[TBL] [Abstract][Full Text] [Related]
33. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.
Kavallaris M; Tait AS; Walsh BJ; He L; Horwitz SB; Norris MD; Haber M
Cancer Res; 2001 Aug; 61(15):5803-9. PubMed ID: 11479219
[TBL] [Abstract][Full Text] [Related]
34. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules.
Himes RH
Pharmacol Ther; 1991; 51(2):257-67. PubMed ID: 1784631
[TBL] [Abstract][Full Text] [Related]
35. Divalent cation and ionic strength effects on Vinca alkaloid-induced tubulin self-association.
Lobert S; Boyd CA; Correia JJ
Biophys J; 1997 Jan; 72(1):416-27. PubMed ID: 8994628
[TBL] [Abstract][Full Text] [Related]
36. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity.
Lobert S; Ingram JW; Hill BT; Correia JJ
Mol Pharmacol; 1998 May; 53(5):908-15. PubMed ID: 9584218
[TBL] [Abstract][Full Text] [Related]
37. Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20'-vinblastine congeners that lack antimicrotubule activity.
Borman LS; Bornmann WG; Kuehne ME
Cancer Chemother Pharmacol; 1993; 31(5):343-9. PubMed ID: 8431967
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and evaluation of hybrid molecules targeting the vinca domain of tubulin.
Gherbovet O; Sánchez-Murcia PA; García Alvarez MC; Bignon J; Thoret S; Gago F; Roussi F
Org Biomol Chem; 2015 Mar; 13(10):3144-54. PubMed ID: 25634805
[TBL] [Abstract][Full Text] [Related]
39. Interaction of cryptophycin 1 with tubulin and microtubules.
Kerksiek K; Mejillano MR; Schwartz RE; Georg GI; Himes RH
FEBS Lett; 1995 Dec; 377(1):59-61. PubMed ID: 8543019
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
